Skip to main content

Table 2 Baseline characteristics of the subjects according to follow-up outcomes

From: A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease

Variables

Subjects developed NAFLD (n = 1390)

Subjects did not develop NAFLD (n = 3149)

P

Gender (male/female, n)

1109/281

1887/1262

<  0.001

Age (years)

41.0(34.0–51.0)

41.0 (35.0–51.0)

0.226

BMI (kg/m2)

23.9 (22.2–25.3)

21.5 (19.9–23.3)

<  0.001

SBP (mmHg)

122.0 (114.0–131.0)

116.0 (107.0–126.0)

<  0.001

DBP (mmHg)

78.0 (72.0–84.0)

74.0 (68.0–80.0)

<  0.001

WC (cm)

82.0 (77.0–87.0)

74.0 (69.0–80.0)

<  0.001

TyG

8.58 (8.25–8.91)

8.21 (7.91–8.54)

<  0.001

BUN (μmol/l)

5.03 (4.23–5.86)

4.95 (4.19–5.75)

0.029

Cr (μmol/l)

75.0 (65.0–83.0)

70.0 (59.0–80.0)

<  0.001

FPG (mmol/l)

4.47 (4.15–4.82)

4.43 (4.14–4.77)

0.114

UA (μmol/l)

347.0 (294.0–401.0)

301.0 (245.0–356.0)

<  0.001

AST (U/l)

20.0 (17.0–24.0)

19.0 (16.0–22.0)

<  0.001

ALT (U/l)

26.0 (19.0–37.0)

19.0 (14.0–26.0)

<  0.001

y-GGT (U/l)

21.0 (15.0–33.0)

15.0 (11.0–22.0)

<  0.001

TC (mmol/l)

4.77 (4.17–5.41)

4.61 (4.03–5.24)

<  0.001

TG (mmol/l)

1.48 (1.10–2.04)

1.03 (0.79–1.39)

<  0.001

HDL-C (mmol/l)

1.20 (1.05–1.43)

1.33 (1.10–1.64)

<  0.001

LDL-C (mmol/l)

2.73 (2.26–3.26)

2.52 (2.04–3.05)

<  0.001

Apo-A1 (g/l)

1.26 (1.11–1.45)

1.35 (1.16–1.53)

<  0.001

Apo-B (g/l)

0.95 (0.80–1.14)

0.86 (0.72–1.03)

<  0.001

eGFR (ml/(min·1.73 m2))

108.1 (96.5–121.9)

110.8 (98.4–125.8)

<  0.001